Bristol's Immuno-Oncology Leadership Stake Lies In Ipilimumab's Promise
Executive Summary
During Bristol-Myers Squibb's investor day March 4, management's enthusiasm for an important late-stage drug in development for metastatic melanoma, ipilimumab, was palpable. CEO designate Lamberto Andreotti told the room full of analysts and investors that ipilimumab "has the potential to become a paradigm changer in the emerging field of immuno-oncology.
You may also be interested in...
Pfizer Sets Its Sights On Therapeutic Cancer Vaccines
The big pharma, which has failed to keep up with rivals in the immuno-oncology field, plans to bring a therapeutic cancer vaccine into the clinic in the next 18 to 24 months, vaccine R&D head Emilio Emini said during a media briefing at the company’s headquarters Sept. 10.
Pfizer Sets Its Sights On Therapeutic Cancer Vaccines
The big pharma, which has failed to keep up with rivals in the immuno-oncology field, plans to bring a therapeutic cancer vaccine into the clinic in the next 18 to 24 months, vaccine R&D head Emilio Emini said during a media briefing at the company’s headquarters Sept. 10.
Bristol-Myers Taps Academia To Help Research Immuno-Oncology Pipeline
Inspired by the correlative research during the clinical trials for Yervoy, BMS teams up with ten institutions from across the globe to find biomarkers in post-response data.